Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin

International Journal of Gynecological Pathology

Volumn 27, Issue 4, 2008, Pages 491-495

  Kanner, William A ^a   Galgano, Mary T ^a   Stoler, Mark H ^a   Mills, Stacey E ^a   Atkins, Kristen A ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Breast carcinoma; BRST 2; GCDFP 15; Mammaglobin; Mesothelin; Micropapillary; Ovary; Serous carcinoma; UPSC

Indexed keywords

GROSS CYSTIC DISEASE FLUID PROTEIN 15; MAMMAGLOBIN; MESOTHELIN; MONOCLONAL ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG; CARRIER PROTEIN; GLYCOPROTEIN; MEGAKARYOCYTE POTENTIATING FACTOR; MEMBRANE PROTEIN; PIP PROTEIN, HUMAN; TUMOR PROTEIN; UTEROGLOBIN;

ARTICLE; BREAST CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; MULLERIAN SEROUS CARCINOMA; OVARY CARCINOMA; OVARY METASTASIS; PRIORITY JOURNAL; UTERINE CERVIX; UTERUS CARCINOMA; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; METABOLISM; OVARY TUMOR; PAGET NIPPLE DISEASE; PAPILLARY CARCINOMA; PATHOLOGY; RETROSPECTIVE STUDY; UTERUS CANCER;

ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CARCINOMA, PAPILLARY; CARRIER PROTEINS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; UTERINE NEOPLASMS; UTEROGLOBIN;

EID: 58149182008     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31817d5340     Document Type: Article

References (37)

1. DeYoung BR, Wick MR. Immunohistologic evaluation of metastatic carcinomas of unknown origin: an algorithmic approach. Semin Diagn Pathol 2000;17:184-93.
2. Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol 2001;116:246-52.
3. Hwang H, Quenneville L, Yaziji H, et al. Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol 2004;12:122-6.
4. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283-90.
5. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol 2002;117:745-50.
6. Loy TS, Quesenberry JT, Sharp SC. Distribution of CA 125 in adenocarcinomas. An immunohistochemical study of 481 cases. Am J Clin Pathol 1992;98:175-9.
7. Mazoujian G, Pinkus GS, Davis S, et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983;110:105-12.
8. Monteagudo C, Merino MJ, LaPorte N, et al. Value of gross cystic disease fluid protein-15 in distinguishing metastatic breast carcinomas among poorly differentiated neoplasms involving the ovary. Hum Pathol 1991;22:368-72.
9. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
10. Recine MA, Deavers MT, Middleton LP, et al. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall. Am J Surg Pathol 2004;28:1646-51.
11. Shimizu M, Toki T, Takagi Y, et al. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000;19:158-63.
12. Silberstein GB, Van Horn K, Strickland P, et al. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proc Natl Acad Sci USA 1997;94:8132-7.
13. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005;29:1482-9.
14. Wick MR, Lillemoe TJ, Copland GT, et al. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol 1989;20:281-7.
15. Goldstein NS, Uzieblo A. WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 2002;117:541-5.
16. Watson MA, Fleming TP. Mammaglobin, a mammary-specific member of the uteroglobin gene family, is overexpressed in human breast cancer. Cancer Res 1996;56:860-5.
17. Watson MA, Fleming TP. Isolation of differentially expressed sequence tags from human breast cancer. Cancer Res 1994;54:4598-602.
18. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 2007;127:103-13.
19. Zafrakas M, Petschke B, Donner A, et al. Expression analysis of mammaglobin A (SCGB2A2) and lipophilin B (SCGB1D2) in more than 300 human tumors and matching normal tissues reveals their co-expression in gynecologic malignancies. BMC Cancer 2006;6:88.
20. Frierson HF Jr, Moskaluk CA, Powell SM, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol 2003;34:605-9.
21. Ordonez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-28.
22. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996;93:136-40.
23. Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-7.
24. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-51.
25. Luna-More S, Casquero S, Perez-Mellado A, et al. Importance of estrogen receptors for the behavior of invasive micropapillary carcinoma of the breast. Review of 68 cases with follow-up of 54. Pathol Res Pract 2000;196:35-9.
26. Luna-More S, de los Santos F, Breton JJ, et al. Estrogen and progesterone receptors, c-erbB-2, p53, and Bcl-2 in thirty-three invasive micropapillary breast carcinomas. Pathol Res Pract 1996;192:27-32.
27. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
28. Cormio G, di Vagno G, Melilli GA, et al. Ovarian carcinoma metastatic to the breast. Gynecol Obstet Invest 2001;52:73-4.
29. Cormio G, Rossi C, Cazzolla A, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer 2003;13:125-9.
30. Hajdu SI, Urban JA. Cancers metastatic to the breast. Cancer 1972;29:1691-6.
31. Raptis S, Kanbour AI, Dusenbery D, et al. Fine-needle aspiration cytology of metastatic ovarian carcinoma to the breast. Diagn Cytopathol 1996;15:1-6.
32. Rose PG, Piver MS, Tsukada Y, et al. Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. Cancer 1989;64:1508-13.
33. Gagnon Y, Tetu B. Ovarian metastases of breast carcinoma. A clinicopathologic study of 59 cases. Cancer 1989;64:892-8.
34. Han JH, Kang Y, Shin HC, et al. Mammaglobin expression in lymph nodes is an important marker of metastatic breast carcinoma. Arch Pathol Lab Med 2003;127:1330-4.
35. McCluggage WG, Wilkinson N. Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology 2005;47:231-47.
36. Zhu W, Michael CW. WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions. Diagn Cytopathol 2007;35:370-5.
37. Chang K, Pastan I, Willingham MC. Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992;50:373-81.